

## FEBRUARY 2025

Date	Headline and Source	Link	Summary
2 <sup>nd</sup> February	Customs duty relief for critical medicines under Patient Assistance Programmes The Hindu Business Line, February 02, 2025	<a href="#">Customs duty relief for critical medicines under Patient Assistance Programmes</a>	Anil Matai, Director-General, Organisation of Pharmaceutical Producers of India (OPPI), agreed the BCD exemption would help expand the programme to more patients, besides encouraging more companies to participate in similar schemes.
2 <sup>nd</sup> February	How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry BioSpectrum India, February 02, 2025	<a href="#">How AI Innovations at GCCs Solidifying India's Position in Global Life Sciences Industry</a>	Telangana is home to leading R&D centres like Novartis Biome, Hyderabad's first innovation hub, which focuses on integrating AI into pharmaceutical research. It collaborates with startups, researchers, and academic institutions to drive advancements in drug discovery and clinical trials.
3 <sup>rd</sup> February	Sanofi Healthcare Gets CDSCO Panel Nod To Study Amlitelimab for atopic dermatitis Medical Dialogues, February 03, 2025	<a href="#">Sanofi Healthcare Gets CDSCO Panel Nod To Study Amlitelimab for atopic dermatitis</a>	Drug major Sanofi Healthcare India has got approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical trial of amlitelimab in adult participants with moderate to severe atopic dermatitis.
4 <sup>th</sup> February	OPPI sees Union Budget 2025 paves way for an innovation-driven healthcare landscape in India PharmaBiz, February 04, 2025	<a href="#">OPPI sees Union Budget 2025 paves way for an innovation-driven healthcare landscape in India</a>	Organisation of Pharmaceutical Producers of India (OPPI) sees that initiatives collectively pave the way for a stronger, more inclusive, and innovation-driven healthcare landscape in India. Anil Matai, director general, OPPI, said that this year budget reflects the government's strong commitment to strengthening India's healthcare ecosystem through progressive and patient-centric initiatives.
4 <sup>th</sup> February	Union Budget 2025-26: Healthcare, Industry Responds Medical Buyer, February 04, 2025	<a href="#">Union Budget 2025-26: Healthcare, Industry Responds</a>	The corresponding figure was Rs 90,958.63 crore in FY25. The government also allocated Rs 9,406 crore for the Ayushman Bharat Pradhan Mantri Jan Arogya Yojana (AB PM-JAY), and Rs 4,200 crore for the Pradhan Mantri Ayushman Bharat Health Infrastructure Mission (PMABHIM). (Organisation of Pharmaceutical Producers of India)
4 <sup>th</sup> February	Metropolis Healthcare, Roche team up to launch HPV DNA testing in India Business Standard, February 04, 2025	<a href="#">Metropolis Healthcare, Roche team up to launch HPV DNA testing in India</a>	Metropolis Healthcare on Monday announced its collaboration with Roche Diagnostics India and Neighbouring Markets to introduce self-sampling human papillomavirus (HPV) DNA test for cervical

			cancer screening in India. The HPV test will be rolled out on February 4 to coincide with World Cancer Day, an official with Metropolis said.
4 <sup>th</sup> February	Eli Lilly likely to launch weight loss & anti-diabetes drug in India: Is it safe to consume? Live Mint, February 04, 2025	<a href="#">Eli Lilly likely to launch weight loss &amp; anti-diabetes drug in India: Is it safe to consume?</a>	US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from the company. Eli Lilly sells Tirzepatide under the name of Mounjaro, a prescription-based medication that has to be injected once a week.
7 <sup>th</sup> February	Boehringer Ingelheim India and EMRI Green Health Services a GVK Enterprise Sign MoU to Transform Prehospital Stroke Care in India ANI News, February 07, 2025	<a href="#">Boehringer Ingelheim India and EMRI Green Health Services a GVK Enterprise Sign MoU to Transform Prehospital Stroke Care in India</a>	Boehringer Ingelheim India has signed a Memorandum of Understanding (MoU) with Hyderabad-based EMRI Green Health Services a GVK enterprise, the operator of the Government-funded 108 National Emergency Ambulance Service to enhance prehospital stroke care management across India.
9 <sup>th</sup> February	Boehringer Ingelheim India Partners with EMRI Green Health Services Transforming PreHospital Stroke Care in India E Health, February 09, 2025	<a href="#">Boehringer Ingelheim India Partners with EMRI Green Health Services Transforming PreHospital Stroke Care in India</a>	Recognizing this challenge, Boehringer Ingelheim India has entered into a strategic partnership with EMRI Green Health Services, a GVK enterprise that operates the Government-funded 108 National Emergency Ambulance Service, to enhance prehospital stroke care across the country.
9 <sup>th</sup> February	Roche announces detailed analysis of phase III REGENCY trial of Gazyva/Gazyvaro in people with active lupus nephritis published in the New England Journal of Medicine PharmaBiz, February 09, 2025	<a href="#">Roche announces detailed analysis of phase III REGENCY trial of Gazyva/Gazyvaro in people with active lupus nephritis published in the New England Journal of Medicine</a>	Roche announced that a detailed analysis of its phase III REGENCY trial of Gazyva/Gazyvaro (obinutuzumab) in people with active lupus nephritis (LN) was published in the New England Journal of Medicine.
10 <sup>th</sup> February	CDSCO Panel Approves Novo Nordisk Proposal Amendment Proposal for Etavopivat study Medical Dialogues, February 10, 2025	<a href="#">CDSCO Panel Approves Novo Nordisk Proposal Amendment Proposal for Etavopivat study</a>	The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has approved the protocol amendment proposal presented by pharmaceutical major Novo Nordisk to study Etavopivat 200 mg in people with sickle cell disease.
11 <sup>th</sup> February	Sanofi launches Rezurock against chronic Graftversushost disease in India The Economic Times, February 11, 2025	<a href="#">Sanofi launches Rezurock against chronic Graftversushost disease in India</a>	Drugmaker Sanofi Healthcare India on Monday said it has received marketing authorization for Rezurock (belumosudil tablets) in India for treatment of chronic Graftversushost disease (GVHD) in patients 12 years and above.

12 <sup>th</sup> February	J&J Launches TECNIS PureSee Intraocular Lens for Presbyopia in India ET Health World, February 12, 2025	<a href="#">J&amp;J Launches TECNIS PureSee Intraocular Lens for Presbyopia in India</a>	Johnson & Johnson (J&J) has introduced the TECNIS PureSee, a purely refractive intraocular lens (IOL) designed for individuals with presbyopia, in India. The TECNIS PureSee IOL delivers uninterrupted, high-quality vision with best-in-class contrast and low-light performance, comparable to a monofocal IOL.
16 <sup>th</sup> February	MSD Pharma, Delhi Capitals partner to create awareness about cervical cancer prevention The Economic Times, February 16, 2025	<a href="#">MSD Pharma, Delhi Capitals partner to create awareness about cervical cancer prevention</a>	Biopharmaceutical company MSD Pharmaceuticals and WPL team Delhi Capitals have announced a partnership to raise awareness about cervical cancer prevention across India. The collaboration aims to leverage the growing influence of women's sports to educate women and families on the importance of preventive health and raise awareness about protecting oneself from cervical cancer, a statement said on Saturday.
18 <sup>th</sup> February	Johnson and Johnson Gets CDSCO Panel Nod To study Guselkumab in Psoriatic Arthritis Medical Dialogues, February 18, 2025	<a href="#">Johnson and Johnson Gets CDSCO Panel Nod To study Guselkumab in Psoriatic Arthritis</a>	Pharmaceutical major Johnson and Johnson has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the Phase IV clinical trial of Guselkumab in order to evaluate the safety and efficacy of Guselkumab administered subcutaneously in the treatment of Indian patients with psoriatic arthritis.
20 <sup>th</sup> February	IIT Madras teams up with Switzerland-based Roche for R&D Millennium Post, February 20, 2025	<a href="#">IIT Madras teams up with Switzerland-based Roche for R&amp;D</a>	IIT Madras Centre for Responsible AI (CeRAI) has teamed up with Roche Diagnostics International Ltd, Switzerland, for collaboration in R&D. Roche is joining CeRAI as a Gold Consortium Member with a MoU signed between the two organisations.
24 <sup>th</sup> February	Novartis picks next-gen innovators paving way for healthcare breakthroughs BioSpectrum India, February 24, 2025	<a href="#">Novartis picks next-gen innovators paving way for healthcare breakthroughs</a>	An initiative by Novartis to nurture the brightest minds in data science and technology Novartis India, a focused innovative medicines company, successfully concluded the grand finale of NEST (Nurturing Excellence, Strengthening Talent) a first-of-its-kind, real-world case-based competition focused on healthcare innovation.
24 <sup>th</sup> February	Pfizer Partners with Mylan to Boost Ativan and Pacitane Sales in India India Infoline, February 24, 2025	<a href="#">Pfizer Partners with Mylan to Boost Ativan and Pacitane Sales in India</a>	Pfizer Ltd has entered into a strategic marketing and supply agreement with Mylan Pharmaceuticals Private Limited to strengthen the distribution and sales of Ativan and Pacitane in India. It is a five-year agreement that was effective upon approval

			by Pfizer s Board of Directors on February 21, 2025.
24 <sup>th</sup> February	Novo Nordisk Gets CDSCO Panel Nod To study CDR132L Medical Dialogues, February 24, 2025	<a href="#">Novo Nordisk Gets CDSCO Panel Nod To study CDR132L</a>	Novo Nordisk has got the go-ahead from the Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) to conduct the clinical trial of CDR132L 45.2 (45,2) mg/vial, a synthetic oligonucleotide that's being developed to treat heart failure.
25 <sup>th</sup> February	Amgen opens \$200 million technology and innovation hub in Hyderabad Business Standard, February 25, 2025	<a href="#">Amgen opens \$200 million technology and innovation hub in Hyderabad</a>	US drug major Amgen on Monday announced the opening of a new technology and innovation hub, Amgen India, in Hyderabad. With a planned investment of \$200 million through 2025, the facility aims to accelerate the company's medicine pipeline and enhance global operations through advanced artificial intelligence (AI) and data science capabilities.
27 <sup>th</sup> February	US drugmaker Merck to boost workforce in India, executive says The Economic Times, February 27, 2025	<a href="#">US drugmaker Merck to boost workforce in India, executive says</a>	Merck's India sites, which together employ around 1,800 people, focus on multiple therapy areas including oncology, diabetes, vaccines and animal health, as well as technology-related centers. The U.S. drugmaker opened a new technology center in the southern Indian city of Hyderabad this week.
27 <sup>th</sup> February	MSD opens 1st India tech centre in Hyd The Times of India, February 27, 2025	<a href="#">MSD opens 1st India tech centre in Hyd</a>	US pharma giant Merck & Co Inc, which does business as Merck Sharp & Dohme (MSD) outside the United States and Canada, opened its first technology centre in India at Hyderabad this week, according to its executive vice president and chief information digital officer, Dave Williams.
28 <sup>th</sup> February	AstraZeneca, Bayer, Eli Lilly: Why global pharma giants are betting big on India s healthcare revolution Fortune, February 28, 2025	<a href="#">AstraZeneca, Bayer, Eli Lilly: Why global pharma giants are betting big on India s healthcare revolution</a>	Collaborations can help foreign firms navigate regulatory complexities, reduce costs and expand reach, says OPPI s Matai. India s healthcare market, projected to double by 2030, presents significant opportunities, he says.

-----